SAGE — Sage Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $544.97m
- $121.11m
- $41.24m
- 36
- 20
- 82
- 43
Annual income statement for Sage Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,114 | 6.31 | 7.69 | 86.5 | 41.2 |
| Cost of Revenue | |||||
| Gross Profit | 1,114 | 5.75 | 6.87 | 84.3 | 31.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 518 | 467 | 555 | 666 | 474 |
| Operating Profit | 596 | -461 | -547 | -580 | -432 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 606 | -458 | -533 | -541 | -401 |
| Net Income After Taxes | 606 | -458 | -533 | -541 | -401 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 606 | -458 | -533 | -541 | -401 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 606 | -458 | -533 | -541 | -401 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 12 | -7.8 | -8.98 | -8.49 | -6.23 |